Neil Lee Spector, MD

Associate Professor of Medicine
Sandra Coates Associate Professor
Associate Professor of Pharmacology & Cancer Biology
Member of the Duke Cancer Institute
Campus mail 450 Research Drive, B354, Box 91004 Med Ctr, Durham, NC 27708
Phone (919) 668-1094
Email address neil.spector@duke.edu

Education and Training

  • Medical Resident, Medicine, University of Texas at Dallas, 1984 - 1986
  • First Year Neurology Resident, Neurology, University of Texas at Dallas, 1983 - 1984
  • Intern, Medicine, University of Texas at Dallas, 1982 - 1983
  • M.D., University of Medicine and Dentistry of New Jersey, 1982

Publications

Hamilton, Erika, Kimberly Blackwell, Amy C. Hobeika, Timothy M. Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, et al. “Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]..” J Transl Med 10 (February 10, 2012). https://doi.org/10.1186/1479-5876-10-28.

PMID
22325452
Full Text

Il’yasova, Dora, Sharareh Siamakpour-Reihani, Igor Akushevich, Lucy Akushevich, Neil Spector, and Joellen Schildkraut. “What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?.” Breast Cancer Res Treat 130, no. 2 (November 2011): 691–97. https://doi.org/10.1007/s10549-011-1719-4.

PMID
21850396
Full Text

Xia, Wenle, Zuguo Liu, Rongrong Zong, Leihua Liu, Sumin Zhao, Sarah S. Bacus, Yubin Mao, et al. “Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors..” Mol Cancer Ther 10, no. 8 (August 2011): 1367–74. https://doi.org/10.1158/1535-7163.MCT-10-0991.

PMID
21673090
Full Text

Boussen, Hamouda, Massimo Cristofanilli, Tal Zaks, Michelle DeSilvio, Vanessa Salazar, and Neil Spector. “Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer..” J Clin Oncol 28, no. 20 (July 10, 2010): 3248–55. https://doi.org/10.1200/JCO.2009.21.8594.

PMID
20530274
Full Text

Morse, Michael A., Junping Wei, Zachary Hartman, Wenle Xia, Xiu-Rong Ren, Gangjun Lei, William T. Barry, et al. “Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo..” Int J Cancer 126, no. 12 (June 15, 2010): 2893–2903. https://doi.org/10.1002/ijc.24995.

PMID
19856307
Full Text

Hartman, Zachary C., Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, et al. “An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity..” Clin Cancer Res 16, no. 5 (March 1, 2010): 1466–77. https://doi.org/10.1158/1078-0432.CCR-09-2549.

PMID
20179231
Full Text

Xia, Wenle, Sarah Bacus, Intisar Husain, Leihua Liu, Sumin Zhao, Zuguo Liu, M Arthur Moseley, et al. “Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA..” Mol Cancer Ther 9, no. 2 (February 2010): 292–99. https://doi.org/10.1158/1535-7163.MCT-09-1041.

PMID
20124457
Full Text

Spector, Neil L., and Kimberly L. Blackwell. “Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer..” J Clin Oncol 27, no. 34 (December 1, 2009): 5838–47. https://doi.org/10.1200/JCO.2009.22.1507.

PMID
19884552
Full Text

Burris, Howard A., Charles W. Taylor, Suzanne F. Jones, Kevin M. Koch, Melissa J. Versola, Niki Arya, Ronald A. Fleming, et al. “A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies..” Clin Cancer Res 15, no. 21 (November 1, 2009): 6702–8. https://doi.org/10.1158/1078-0432.CCR-09-0369.

PMID
19825948
Full Text

Pages